

CITATION REPORT

List of articles citing

Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects

DOI: 10.1007/s40262-017-0532-6

Clinical Pharmacokinetics, 2017, 56, 1391-1401.

Source: <https://exaly.com/paper-pdf/66226942/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
32	Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 371-377	5.5	9
31	Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 343-351	5.4	7
30	Semaglutide: First Global Approval. <i>Drugs</i> , 2018 , 78, 275-284	12.1	32
29	Semaglutide once-weekly: improved efficacy with a new safety warning. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 1061-1072	3.8	7
28	Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 1529-1538	6.2	13
27	The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date. <i>Drug Design, Development and Therapy</i> , 2019 , 13, 2985-2996	4.4	6
26	A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. <i>Biomedical Chromatography</i> , 2019 , 33, e4663	1.7	8
25	Physiologically-Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid-to-Lactone Conversion. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019 , 8, 664-675	4.5	11
24	Population Pharmacokinetics of Semaglutide for Type 2 Diabetes. <i>Diabetes Therapy</i> , 2019 , 10, 649-662	3.6	6
23	Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 1205-1214	6.2	1
22	Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 1193-1203	6.2	30
21	Semaglutide as a promising antiobesity drug. <i>Obesity Reviews</i> , 2019 , 20, 805-815	10.6	33
20	Prediction of Cyclosporin-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Model Characterizing Interplay of Drug Transporters and Enzymes. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	3
19	Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin. <i>Scientific Reports</i> , 2020 , 10, 12457	4.9	6
18	An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020 , 16, 809-822	5.5	21
17	Digoxin: Pharmacology and toxicology-A review. <i>Environmental Toxicology and Pharmacology</i> , 2020 , 79, 103400	5.8	15
16	Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial. <i>Advances in Therapy</i> , 2021 , 38, 550-561	4.1	3

15	Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide. <i>Frontiers in Endocrinology</i> , 2021 , 12, 645507	5.7	5
14	Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 998-1005	6.7	31
13	SUSTAINable management of type 2 diabetes: feasibility of use and safety of semaglutide. <i>Annals of Translational Medicine</i> , 2018 , 6, 129	3.2	
12	Pharmacologically relevant drug interactions of Glucagon-like peptide-1 receptor agonists. <i>Journal of Analytical & Pharmaceutical Research</i> , 2019 , 8, 51-53	0.4	1
11	High-Dose Once-Weekly Semaglutide: A New Option for Obesity Management. <i>Annals of Pharmacotherapy</i> , 2021 , 10600280211053867	2.9	2
10	Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes.. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022 , 1	10.5	4
9	Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care.. <i>Journal of Personalized Medicine</i> , 2022 , 12,	3.6	1
8	The preventive effects of different doses of atorvastatin on contrast-induced acute kidney injury after CT perfusion.. <i>Journal of Clinical Laboratory Analysis</i> , 2022 , e24386	3	
7	Once-Weekly Semaglutide for Weight Management: A Clinical Review. <i>Journal of Pharmacy Technology</i> , 875512252210926	0.6	0
6	Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review. <i>Pharmaceutical Research</i> ,	4.5	0
5	Population pharmacokinetic of paracetamol and atorvastatin with co-administration of semaglutide. <i>Pharmacology Research and Perspectives</i> , 2022 , 10,	3.1	
4	Derivatization with fatty acids in peptide and protein drug discovery.		0
3	Exenatide prevents statin-related LDL receptor increase and improves insulin secretion in pancreatic beta cells (1.1E7) in a protein kinase A-dependent manner. 2022 , 20, 130-140		0
2	Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations. Volume 16, 4449-4461		0
1	Systems Pharmacology and Network Analysis to Advance Pharmacogenomics and Precision Medicine Decisions in Type-2 Diabetes Therapy. 2023 , 3, 329-363		0